MX2021003681A - Composiciones y metodos para el tratamiento de desordenes inflamatorios. - Google Patents
Composiciones y metodos para el tratamiento de desordenes inflamatorios.Info
- Publication number
- MX2021003681A MX2021003681A MX2021003681A MX2021003681A MX2021003681A MX 2021003681 A MX2021003681 A MX 2021003681A MX 2021003681 A MX2021003681 A MX 2021003681A MX 2021003681 A MX2021003681 A MX 2021003681A MX 2021003681 A MX2021003681 A MX 2021003681A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- inflammatory disorders
- benzimidazole derivative
- patient
- compound
- Prior art date
Links
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- -1 benzoimidazole compound Chemical class 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan aquí métodos de tratamiento y prevención del padecimiento inflamatorio del intestino en un paciente. Los métodos aquí provistos comprenden administrar al paciente que lo necesite una cantidad efectiva de un compuesto de benzoimidazol, Compuesto 1, para tratar o prevenir un padecimiento inflamatorio del intestino en un paciente. También se proporcionan formulaciones y rutas de administración del compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740748P | 2018-10-03 | 2018-10-03 | |
| PCT/US2019/054293 WO2020072645A1 (en) | 2018-10-03 | 2019-10-02 | Benzimidazole derivative for use in the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003681A true MX2021003681A (es) | 2021-08-19 |
Family
ID=68468802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003681A MX2021003681A (es) | 2018-10-03 | 2019-10-02 | Composiciones y metodos para el tratamiento de desordenes inflamatorios. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210369678A1 (es) |
| EP (1) | EP3860593A1 (es) |
| JP (1) | JP2022504293A (es) |
| KR (1) | KR20210100594A (es) |
| CN (1) | CN113382729A (es) |
| AU (1) | AU2019355097A1 (es) |
| CA (1) | CA3114592A1 (es) |
| MX (1) | MX2021003681A (es) |
| SG (1) | SG11202103191QA (es) |
| TW (1) | TW202027745A (es) |
| WO (1) | WO2020072645A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY204336A (en) | 2013-06-13 | 2024-08-23 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| EP4138825A1 (en) | 2020-04-20 | 2023-03-01 | Akebia Therapeutics Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| WO2022251563A1 (en) | 2021-05-27 | 2022-12-01 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
| KR102729791B1 (ko) | 2022-04-13 | 2024-11-14 | 재단법인 대구경북첨단의료산업진흥재단 | 아릴에텐 유도체를 유효성분으로 포함하는 염증성 장질환 치료용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101390144B1 (ko) * | 2006-04-13 | 2014-04-28 | 다이호야쿠힌고교 가부시키가이샤 | 염증성 장질환 치료제 |
| PT2294066E (pt) * | 2008-04-28 | 2014-11-21 | Janssen Pharmaceutica Nv | Benzoimidazoles como inibidores da prolil-hidroxilase |
| MA40406A (fr) * | 2014-07-28 | 2016-02-04 | Nogra Pharma Ltd | Procédés et compositions de diagnostic et de traitement des maladies inflammatoires chroniques de l'intestin |
-
2019
- 2019-10-02 AU AU2019355097A patent/AU2019355097A1/en not_active Abandoned
- 2019-10-02 CN CN201980079183.1A patent/CN113382729A/zh active Pending
- 2019-10-02 US US17/282,108 patent/US20210369678A1/en not_active Abandoned
- 2019-10-02 WO PCT/US2019/054293 patent/WO2020072645A1/en not_active Ceased
- 2019-10-02 MX MX2021003681A patent/MX2021003681A/es unknown
- 2019-10-02 EP EP19798422.2A patent/EP3860593A1/en not_active Withdrawn
- 2019-10-02 SG SG11202103191QA patent/SG11202103191QA/en unknown
- 2019-10-02 CA CA3114592A patent/CA3114592A1/en not_active Abandoned
- 2019-10-02 KR KR1020217012069A patent/KR20210100594A/ko not_active Withdrawn
- 2019-10-02 JP JP2021518655A patent/JP2022504293A/ja active Pending
- 2019-10-03 TW TW108135867A patent/TW202027745A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210369678A1 (en) | 2021-12-02 |
| EP3860593A1 (en) | 2021-08-11 |
| KR20210100594A (ko) | 2021-08-17 |
| AU2019355097A1 (en) | 2021-05-27 |
| CN113382729A (zh) | 2021-09-10 |
| JP2022504293A (ja) | 2022-01-13 |
| SG11202103191QA (en) | 2021-04-29 |
| TW202027745A (zh) | 2020-08-01 |
| WO2020072645A1 (en) | 2020-04-09 |
| CA3114592A1 (en) | 2020-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003681A (es) | Composiciones y metodos para el tratamiento de desordenes inflamatorios. | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| CR20210368A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2022011804A (es) | Uso de agentes para el tratamiento de condiciones respiratorias. | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| PH12014500472A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12014500371A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| EP4609912A3 (en) | New use of a combination of sacubitril and valsartan | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| WO2019118779A3 (en) | Peptides and other agents for treating pain and increasing pain sensitivity | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. |